Jan Egbert de Vries
Chairman at Artax, Inc.
Profile
Jan Egbert de Vries is the founder of Tr1x, Inc. He currently serves as the Chairman of Artax, Inc. He previously served as the Non-Executive Chairman of Cassiopea SpA from 2015 to 2021, Chairman of AIMM Therapeutics BV from 2018 to 2020, Director of Schering-Plough Research Institute from 1985 to 1988, Director-Human Immunology Department of DNAX Research, Inc. from 1989 to 1997, Senior VP-Drug Discovery & Early Development of Novartis AG from 1996 to 2009, and Head of Immunology Department of Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh from 1969 to 1985.
He holds a doctorate from the University of Amsterdam and a graduate degree from the University of Utrecht.
Jan Egbert de Vries active positions
Companies | Position | Start |
---|---|---|
Artax, Inc. | Chairman | - |
Former positions of Jan Egbert de Vries
Companies | Position | End |
---|---|---|
Tr1x, Inc.
Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Chief Executive Officer | 16/01/2024 |
AIMM Therapeutics BV
AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Chief Executive Officer | 30/12/2017 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 31/12/2009 |
NOVARTIS AG | Corporate Officer/Principal | 31/12/2008 |
DNAX Research, Inc. | Corporate Officer/Principal | 31/12/1996 |
Training of Jan Egbert de Vries
University of Amsterdam | Doctorate Degree |
University of Utrecht | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private companies | 8 |
---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
Cassiopea SpA
Cassiopea SpA Pharmaceuticals: MajorHealth Technology Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The firm's products include Winlevi, Breezula, Clascoterone Solution, CB-06-02, and CB-06-01. The company was founded on July 30, 2013 and is headquartered in Milan, Italy. | Health Technology |
DNAX Research, Inc. | |
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenh Investment Trusts/Mutual FundsMiscellaneous Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands. | Miscellaneous |
AIMM Therapeutics BV
AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Artax, Inc. | |
Tr1x, Inc.
Tr1x, Inc. Miscellaneous Commercial ServicesCommercial Services Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Jan Egbert de Vries